PD-L1 is largely used as the anti-tumor immunity target and VEGF-A is the anti-angiogenic target which are applied in trials concerning non-small cells lung carcinoma (NSCLC), renal cell carcinoma ovarian cancer patients and many other cancers as melanoma [165] where the data, although promising, remain partial. This evidence concerns the gene VEGFA and neoplasm.